Farxiga (far-SEE-guh) for type 2 diabetes will soon hit shelves

March 2014

Farxiga (far-SEE-guh) for type 2 diabetes will soon hit shelves.

Think of Farxiga (dapagliflozin) as similar to Invokana (canagliflozin). They increase glucose excretion in the urine by inhibiting sodium-glucose co-transporter 2 (SGLT2) in the kidney.

Both lower A1C by about 1%...decrease weight by about 4 to 7 pounds...modestly lower BP...and slightly increase LDL cholesterol.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Hypertension how to manage hypertension in diabetes patients
Drug Testing emphasis on using urine drug testing for monitoring controlled substances in chronic pain patients
Women's Health The new drug Duavee (DEW-ah-vee) and new guidelines will raise questions about how to treat menopausal symptoms
Diabetes Farxiga (far-SEE-guh) for type 2 diabetes will soon hit shelves
Respiratory & Allergy the new OTC Nasacort Allergy 24HR
Poison Prevention Poisonings in kids due to PRESCRIPTION drugs are on the rise
Headache The new Fioricet capsules will cause more confusion
Interactions green tea may interfere with some meds
Salt Forms how to choose between drugs that come in different salt forms
Colon Cancer more emphasis on improving colon cancer screening
NSAIDs controversy about whether naproxen is safer in patients with heart disease than other NSAIDs
Hypertension how to manage SEVERE hypertension
Generics skyrocketing costs of GENERIC drugs

Farxiga (far-SEE-guh) for type 2 diabetes will soon hit shelves

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents